Sluggish OTC Monograph Process Can Be Cause For Manufacturer Confusion
This article was originally published in The Rose Sheet
Executive Summary
The disparity between FDA's OTC monographs and its recommendations based on up-to-date information can create confusion for manufacturers, Office of New Drugs Director John Jenkins acknowledged at the Drug Information Association's conference in Boston June 26